These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9880407)

  • 1. Neuroprotection for acute stroke: making clinical trials work.
    Muir KW; Grosset DG
    Stroke; 1999 Jan; 30(1):180-2. PubMed ID: 9880407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions.
    Gladstone DJ; Black SE; Hakim AM;
    Stroke; 2002 Aug; 33(8):2123-36. PubMed ID: 12154275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection as initial therapy in acute stroke. Third Report of an Ad Hoc Consensus Group Meeting. The European Ad Hoc Consensus Group.
    Cerebrovasc Dis; 1998; 8(1):59-72. PubMed ID: 9645985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interconversion of stroke scales. Implications for therapeutic trials.
    Muir KW; Grosset DG; Lees KR
    Stroke; 1994 Jul; 25(7):1366-70. PubMed ID: 8023351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection.
    Legos JJ; Lenhard SC; Haimbach RE; Schaeffer TR; Bentley RG; McVey MJ; Chandra S; Irving EA; Andrew A Parsons ; Barone FC
    Exp Neurol; 2008 Jul; 212(1):53-62. PubMed ID: 18462720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective therapy in acute ischemic stroke.
    Thurston SE
    Va Med Q; 1998; 125(2):131-2. PubMed ID: 9577717
    [No Abstract]   [Full Text] [Related]  

  • 8. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke.
    Dorman PJ; Sandercock PA
    Stroke; 1996 Sep; 27(9):1507-15. PubMed ID: 8784121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.
    Muir KW
    Stroke; 2002 Jun; 33(6):1545-50. PubMed ID: 12052989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cerebrovascular diseases: state of the art and perspectives.
    Toni D; Gallo V; Falcou A; Argentino C; Fieschi C
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S83-6. PubMed ID: 11811386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective therapies in stroke.
    Zivin JA
    Drugs; 1997; 54 Suppl 3():83-8; discussion 88-9. PubMed ID: 9360855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture.
    Ginsberg MD
    Stroke; 2003 Jan; 34(1):214-23. PubMed ID: 12511777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ischemic penumbra: a new opportunity for neuroprotection.
    Fisher M
    Cerebrovasc Dis; 2006; 21 Suppl 2():64-70. PubMed ID: 16651816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Past, present and future of neuroprotection].
    Mracek J
    Cas Lek Cesk; 2010; 149(12):586-90. PubMed ID: 21387585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy.
    Weir CJ; Kaste M; Lees KR;
    Stroke; 2004 Sep; 35(9):2111-6. PubMed ID: 15243146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for early intervention in acute stroke.
    Albers GW
    Am J Cardiol; 1997 Aug; 80(4C):4D-10D; discussion 35D-39D. PubMed ID: 9284038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does effect of a neuroprotective agent on volume of experimental animal cerebral infarct predict effect of the agent on clinical outcome in human stroke?
    Jonas S; Tran AQ; Eisenberg E; Azam M; Viera D; Grumet S
    Ann N Y Acad Sci; 1997 Oct; 825():281-7. PubMed ID: 9369994
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial.
    Tilley BC; Marler J; Geller NL; Lu M; Legler J; Brott T; Lyden P; Grotta J
    Stroke; 1996 Nov; 27(11):2136-42. PubMed ID: 8898828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection in acute ischemic stroke.
    De Keyser J; Uyttenboogaart M; Koch MW; Elting JW; Sulter G; Vroomen PC; Luijckx GJ
    Acta Neurol Belg; 2005 Sep; 105(3):144-8. PubMed ID: 16255152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group.
    De Deyn PP; Reuck JD; Deberdt W; Vlietinck R; Orgogozo JM
    Stroke; 1997 Dec; 28(12):2347-52. PubMed ID: 9412612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.